CONFERENCE
COMMITTEE REP. NO. 235-22
Honolulu, Hawaii
, 2022
RE: H.B. No. 2260
H.D. 1
S.D. 2
C.D. 1
Honorable Scott K. Saiki
Speaker, House of Representatives
Thirty-First State Legislature
Regular Session of 2022
State of Hawaii
Honorable Ronald D. Kouchi
President of the Senate
Thirty-First State Legislature
Regular Session of 2022
State of Hawaii
Sirs:
Your Committee on Conference on the disagreeing vote of the House of Representatives to the amendments proposed by the Senate in H.B. No. 2260, H.D. 1, S.D. 2, entitled:
"A BILL FOR AN ACT RELATING TO CANNABIS,"
having met, and after full and free discussion, has agreed to recommend and does recommend to the respective Houses the final passage of this bill in an amended form.
The purpose of this measure is to:
(1) Amend the circumstances under which medical cannabis may be transported by and between dispensaries;
(2) Increase the allowable number of plants for production centers;
(3) Increase the number of production centers that may be allowed under a dispensary license;
(4) Increase the number of retail dispensing locations that may be allowed under a dispensary license; and
(5) Redefine the term "medical cannabis production center" to include any series of structures located within the same secured perimeter fence-line.
Your Committee on Conference finds that the State's Medical Cannabis Dispensary Program was established to ensure that qualifying patients have safe and legal access to medical cannabis. Your Committee on Conference also finds that the Medical Cannabis Dispensary Program needs to be updated to increase access to medical cannabis in rural areas, provide the Department of Health with improved administrative control, and increase the supply of medical cannabis in the State.
Your Committee on Conference further finds that to ensure that the existing medical dispensary licensing framework sufficiently meets the needs of qualifying patients in a cost-effective manner, an assessment of the dispensary licensing framework is necessary. In order to maintain the status quo while the assessment is being conducted, an extension of the deadline by which primary caregivers can no longer cultivate cannabis for a qualifying patient is therefore necessary.
Accordingly,
your Committee on Conference has amended this measure by:
(1) Extending the date after which a primary
caregiver is no longer authorized to cultivate cannabis for a qualifying
patient to December 31, 2024;
(2) Deleting provisions that would have increased
the number of retail dispensing locations allowed under a dispensary license;
(3) Limiting licensees to no more than fifteen
thousand cannabis plants in total across all of the licensee's production centers;
(4) Requiring the Department of Health to
establish the fee structure for the submission of applications for additional
production centers and for dispensary-to-dispensary sales;
(5) Permitting a selling dispensary to transport
no more than eight hundred ounces of cannabis or manufactured cannabis products
to a purchasing dispensary within a thirty-day period;
(6) Inserting an appropriation amount of $50,000
for an assessment of the medical cannabis dispensary licensing framework by the
Department of Health;
(7) Changing its effective date to July 1, 2022;
and
(8) Making technical, nonsubstantive amendments
for the purposes of clarity, consistency, and style.
As affirmed by the record of votes of the managers of your Committee on Conference that is attached to this report, your Committee on Conference is in accord with the intent and purpose of H.B. No. 2260, H.D. 1, S.D. 2, as amended herein, and recommends that it pass Final Reading in the form attached hereto as H.B. No. 2260, H.D. 1, S.D. 2, C.D. 1.
Respectfully submitted on behalf of the managers:
ON THE PART OF THE SENATE |
|
ON THE PART OF THE HOUSE |
____________________________ JARRETT KEOHOKALOLE Chair |
|
____________________________ RYAN I. YAMANE Co-Chair |
____________________________ ROSALYN H. BAKER Co-Chair |
|
____________________________ AARON LING JOHANSON Co-Chair |
____________________________ KARL RHOADS Co-Chair |
|
____________________________ ADRIAN K. TAM Co-Chair |
____________________________ DRU KANUHA Co-Chair |
|
|